OpenURL Connection Search

Select item for more details and to access through your institution.

Phosphoproteomics reveals that Parkinson’s disease kinase LRRK2 regulates a subset of Rab GTPases.
Published in:
eLife, 2016, p. 1, doi. 10.7554/eLife.12813
By:
- Steger, Martin;
- Tonelli, Francesca;
- Ito, Genta;
- Davies, Paul;
- Trost, Matthias;
- Vetter, Melanie;
- Wachter, Stefanie;
- Lorentzen, Esben;
- Duddy, Graham;
- Wilson, Stephen;
- Baptista, Marco A. S.;
- Fiske, Brian K.;
- Fell, Matthew J.;
- Morrow, John A.;
- Reith, Alastair D.;
- Alessi, Dario R.;
- Mann, Matthias
Publication type:
Article
The Current State-of-the Art of LRRK2-Based Biomarker Assay Development in Parkinson's Disease.
Published in:
Frontiers in Neuroscience, 2020, p. N.PAG, doi. 10.3389/fnins.2020.00865
By:
- Rideout, Hardy J.;
- Chartier-Harlin, Marie-Christine;
- Fell, Matthew J.;
- Hirst, Warren D.;
- Huntwork-Rodriguez, Sarah;
- Leyns, Cheryl E. G.;
- Mabrouk, Omar S.;
- Taymans, Jean-Marc
Publication type:
Article
Glucocerebrosidase activity and lipid levels are related to protein pathologies in Parkinson's disease.
Published in:
NPJ Parkinson's Disease, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41531-023-00517-w
By:
- Leyns, Cheryl E. G.;
- Prigent, Alice;
- Beezhold, Brenna;
- Yao, Lihang;
- Hatcher, Nathan G.;
- Tao, Peining;
- Kang, John;
- Suh, EunRan;
- Van Deerlin, Vivianna M.;
- Trojanowski, John Q.;
- Lee, Virginia M. Y.;
- Kennedy, Matthew E.;
- Fell, Matthew J.;
- Henderson, Michael X.
Publication type:
Article
LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits.
Published in:
Science Translational Medicine, 2020, v. 12, n. 540, p. 1, doi. 10.1126/scitranslmed.aav0820
By:
- Baptista, Marco A. S.;
- Merchant, Kalpana;
- Barrett, Ted;
- Bhargava, Sakshi;
- Bryce, Dianne K.;
- Ellis, J. Michael;
- Estrada, Anthony A.;
- Fell, Matthew J.;
- Fiske, Brian K.;
- Fuji, Reina N.;
- Galatsis, Paul;
- Henry, Anastasia G.;
- Hill, Sue;
- Hirst, Warren;
- Houle, Christopher;
- Kennedy, Matthew E.;
- Liu, Xingrong;
- Maddess, Matthew L.;
- Markgraf, Carrie;
- Mei, Hong
Publication type:
Article
LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology progression.
Published in:
Translational Neurodegeneration, 2024, v. 13, n. 1, p. 1, doi. 10.1186/s40035-024-00403-2
By:
- Lubben, Noah;
- Brynildsen, Julia K.;
- Webb, Connor M.;
- Li, Howard L.;
- Leyns, Cheryl E. G.;
- Changolkar, Lakshmi;
- Zhang, Bin;
- Meymand, Emily S.;
- O'Reilly, Mia;
- Madaj, Zach;
- DeWeerd, Daniella;
- Fell, Matthew J.;
- Lee, Virginia M. Y.;
- Bassett, Dani S.;
- Henderson, Michael X.
Publication type:
Article

Found: 5

Phosphoproteomics reveals that Parkinson’s disease kinase LRRK2 regulates a subset of Rab GTPases.

The Current State-of-the Art of LRRK2-Based Biomarker Assay Development in Parkinson's Disease.

Glucocerebrosidase activity and lipid levels are related to protein pathologies in Parkinson's disease.

LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits.

LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology progression.